Colorado BioScience Association Names Jack Wheeler Chairperson, Announces 2007 Sponsors and Appoints Eight New Board Members.

Publication: Business Wire

Bookmark this article Print this article Link to this article Email this article Digg It! Add to del.icio.us RSS

COPYRIGHT 2007 Business Wire

DENVER -- Jack Wheeler, CEO of MicroPhage, Inc. (http://www.micro-phage.com), Longmont, was named chairperson of the board of directors for the Colorado BioScience Association (CBSA) at its 2007 annual all-member meeting held at the GlobeImmune/Replidyne dual headquarters facility in Louisville, Colo., April 24. The announcement is made by Denise Brown, CBSA executive director, who says Wheeler assumes chairperson responsibilities from Ed Wood, ArcScan, Inc.

Prior to introducing Wheeler to the CBSA membership, Wood announced the following 2007 association sponsors: Platinum - Amgen, Colorado Science + Technology Park at Fitzsimons, Hogan & Hartson, Colorado State University, Cooley Godward Kronish L.L.P., and University of Colorado Technology Transfer. Silver - Faegre & Benson L.L.P., Pfizer, Fitzsimons Redevelopment Authority, Ernst & Young, ABD Insurance and Financial Services, Metro Denver Economic Development Corporation, Gambro, and Snell & Wilmer, L.L.P. Bronze - Johnson and Johnson, Commerce Bank, Holland & Hart, Fairfield and Woods, P.C., PhRMA, OSI Pharmaceuticals, CBR International and vcfo.

New vice chairperson of the CBSA board is Rick Jory, CEO of Sandhill Scientific (http://www.sandhillsci.com), headquartered in Highlands Ranch. In other action, eight new board members were appointed, expanding the CBSA board to 40 members.

The CBSA board is comprised of members from traditional biotechnology companies, traditional medical device companies, research organizations, service providers and emerging companies. New CBSA board members receiving three-year appointments include: Derek Cole, Allos Therapeutics; Doug Henston, Solix Biofuels; Chris Lepore, Johnson & Johnson; Dan Mitchell, Sequel Venture Partners; Harry Ross, Aweida Venture Partners; Michael Salem, National Jewish Medical and Research Center; Greg Tucker, OSI Pharmaceuticals; and M. Roy Wilson, University of Colorado.

Bios follow of the newly appointed board members:

* Derek Cole, Vice President Investor Relations for Allos Therapeutics (http://www.allos.com), has been involved in the capital markets and strategic planning for over 16 years with 11 years of dedicated...

Read the full article for free courtesy of your local library.